GangaGen's lead product is a proprietary recombinant protein for the topical prevention and treatment of Staplylococcal infections, including infection with methicillin-resistant Staphylococcus aureus (MRSA).
Learn about GangaGen's research »
In addition to treating bacterial diseases, bacteriophage preparations can be used to control or prevent epidemics.
Learn about bacteriophage therapies »
GangaGen is focused on developing products to control multiple species of bacteria pathogenic to humans, particularly antibiotic-resistant strains...
Read more about our industry and the GangaGen founders »